1) Strategic Transformation and Leadership Vision - EssilorLuxottica is undergoing a significant transformation from a traditional optical company to a med-tech and data-driven group, aiming to shape the future of health and human performance. - The company recorded a revenue growth of 18% in Q4 2025 and 11% for the full year, marking a historic double-digit growth. - The introduction of AI glasses has been pivotal, with over 7 million units sold in 2025, driven by strong brand performance from Ray-Ban and Oakley. - The leadership emphasizes the importance of integrating AI glasses into a broader med-tech vision, expanding into areas such as predictive medicine and early detection of health conditions.

2) Financial Performance and Segment Results - Full-year revenue reached EUR 28.5 billion, with adjusted operating profit at EUR 4.5 billion, despite a EUR 300 million headwind from U.S. tariffs and adverse exchange rates. - Q4 performance highlighted a 24% growth in North America, 16% in EMEA, and 12% in Asia Pacific, with Latin America showing an 8% increase. - The company achieved a record free cash flow of EUR 2.8 billion, up EUR 400 million from the previous year.

3) Challenges and Headwinds - The company faced challenges from U.S. tariffs, which impacted gross margins, alongside adverse foreign exchange rates. - The gross margin decreased by 260 basis points year-over-year, attributed mainly to tariffs and the higher contribution of AI glasses to revenue. - Ongoing foreign exchange headwinds are expected to persist into 2026, with a projected impact of about 6 percentage points on results.

4) Operational and Product Plans - EssilorLuxottica plans to expand its capabilities in AI glasses, with a focus on increasing production capacity in partnership with Meta. - The myopia management portfolio grew by 22% in 2025, with Stellest lenses gaining traction, particularly in the U.S. market, where reimbursement coverage is improving. - The company is committed to enhancing its logistics and distribution networks, leveraging both physical retail and e-commerce to drive growth.

5) Guidance and Outlook - The company is optimistic about its long-term outlook, expecting aligned growth of revenues and operating profits over the next five years. - There is a focus on expanding the AI glasses portfolio and enhancing the Stellest product line in the U.S. market. - The transcript lacks specific guidance figures for 2026, particularly regarding expected margin impacts and detailed projections for wearables.

Bottom line: EssilorLuxottica is poised for continued growth driven by its strategic transformation into a med-tech leader, bolstered by strong financial performance and innovative product offerings, despite facing headwinds from tariffs and foreign exchange fluctuations. Shareholders can expect a promising trajectory as the company expands its market presence and product capabilities.